Zoetis Inc. (ZTS) posted strong Q4 2024 earnings in line with analyst estimates, in spite of a 5% drop in share prices, and a drop following
2025 guidance falling short of estimates. However, the earnings and revenue beat the estimates of several Wall Street analysts. Observing a pattern of
stock dips following positive Q4 results and revenues, it's indicated that some entities, such as Chevy Chase Trust Holdings LLC and Sapient Capital LLC, sold their Zoetis shares. Meanwhile, numerous investors, including Asset Management One Co. Ltd., Bright Futures Wealth Management LLC, and Soltis Investment Advisors LLC, purchased Zoetis shares. In other news, a
bird flu vaccine for poultry from Zoetis got conditional approval from the US. The annual results are forecasted to be affirmative by many analysts, and Zoetis declared its second quarter 2025 dividend. Some share price target cuts by analysts led to decreased stock value, but several entities maintain
bullish sentiments towards Zoetis stock. In summary, there is a contrasting landscape in response to Zoetis' recent performance, highlighted by the sale and purchase activities from different stakeholders.
Zoetis ZTS News Analytics from Wed, 27 Nov 2024 08:00:00 GMT to Sat, 15 Feb 2025 14:26:15 GMT -
Rating 0
- Innovation 7
- Information 8
- Rumor -3
